Related Experiment Videos
[Cytogenetic control over the safety of merthiolate]
Abstract:
The capacity of merthiolate (also known as thimerosal), a mercury organic compound used as preservative in vaccines, to induce chromosomal aberrations was studied in vivo in experiments on mice. The metaphasic method of the registration of anomalies was used. In a dose of 3.3 micrograms/kg body weight merthiolate did not produce a damaging effect on the chromosomes of marrow, spleen and embryonal liver cells. Cyclophosphamide (in a dose of 25-50 micrograms/kg) used as positive control induced a significant rise in the frequency of chromosomal transformations.
Insights
Thimerosal, a vaccine preservative, did not cause chromosomal damage in mice at the tested dose. Positive control cyclophosphamide significantly increased chromosomal transformations, validating the study method.
Area of Science:
- Toxicology
- Genetics
- Pharmacology
Background:
- Thimerosal (merthiolate) is an organic mercury compound used as a vaccine preservative.
- Concerns exist regarding the potential genotoxicity of vaccine components.
- In vivo studies are crucial for assessing the safety of pharmaceutical ingredients.
Purpose of the Study:
- To evaluate the in vivo genotoxic potential of thimerosal.
- To determine if thimerosal induces chromosomal aberrations in mouse cells.
- To establish a safety profile for thimerosal as a vaccine preservative.
Main Methods:
- In vivo study utilizing a mouse model.
- Metaphasic method for registering chromosomal anomalies.
- Analysis of chromosomal damage in bone marrow, spleen, and embryonic liver cells.
Main Results:
- Thimerosal, at a dose of 3.3 µg/kg, did not induce chromosomal aberrations.
- Cyclophosphamide (25-50 µg/kg) as a positive control significantly increased chromosomal transformations.
- The study methodology was validated by the positive control's effect.
Conclusions:
- Thimerosal does not appear to be genotoxic at the tested dose in vivo.
- The study provides evidence supporting the safety of thimerosal in vaccine formulations.
- Further research may explore different dosages and exposure durations.